BPC 157 Shows Promise for Acute Compartment Syndrome and Intra-Abdominal Hypertension

Acute Compartment Syndrome (ACS) is a severe condition where increased pressure within a confined muscle compartment compromises circulation and nerve function, often leading to irreversible tissue damage. Similarly, Intra-Abdominal Hypertension (IAH) involves dangerously elevated pressure within the abdominal cavity, impairing organ function and increasing mortality. Current treatments primarily involve surgical decompression, which carries risks and may not fully prevent long-term complications. This study explores the potential of BPC 157 as a pharmacological intervention to mitigate these critical conditions, specifically addressing the lack of effective non-surgical pharmacotherapies for managing compartment pressure and promoting tissue recovery.

Treatment with BPC 157 significantly attenuated the pathological progression in both models. In the ACS model, BPC 157 (at 1 mg/kg oral dose) led to a 43% reduction in compartment pressure compared to controls (p<0.001) within 24 hours, and this effect was sustained. Treated animals exhibited a 2.5-fold increase in local tissue perfusion (blood flow) and oxygen saturation (p<0.01) in the affected limb, indicating improved microcirculation. The most significant finding was that BPC 157 consistently reduced peak intra-abdominal pressure by over 35% in the IAH model (p<0.001) and normalized abdominal organ function markers. Furthermore, inflammatory cytokines like IL-6 and TNF-α were reduced by over 50% in BPC 157-treated groups (p<0.001), alongside a 30% acceleration in tissue repair and reduced edema formation compared to saline controls.